Clinical trials: Biliary Tract Cancers (BTC)
Advanced Biliary Tract Cancer(BTC)
Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.
A Randomized Phase II Study. To assess the difference in objective response rate (ORR) between adult patients with advanced biliary tract cancer assigned to nivolumab plus relatlimab 360 mg/360 mg in combination with GC or…
- Trial name
- NOBLE (NCT07369791)
- Testing
- Nivolumab, Gemcitabine, Cisplatin
- Where
- Taiwan
- Sponsor
- National Health Research Institutes, Taiwan
Biliary Tract Cancer (BTC), First-line Therapy
Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer
Based on unmet clinical needs, relevant research backgrounds, and scientific evidence, it is planned to conduct a prospective, dual-cohort exploratory study.
- Trial name
- NCT07129018
- Testing
- Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Overexpression BTC, Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Moderate/Low BTC
- Volunteers
- 63 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Heptocellular Cancer, Biliary Tract Neoplasms
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Background: Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer.
- Conditions
- Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT01853618
- Testing
- Tremelimumab, RFA, TACE
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Cancer (BTC)
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
The objective of SAFIR-IMPACT BTC is to see whether, combining or replacing the standard adjuvant chemotherapy with a targeted therapy matched to the person's cancer, is better than the standard treatment alone in delaying or…
- Trial name
- SAFIR-IMPACT (NCT07745296)
- Testing
- Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine
- Volunteers
- 990 people
- Sponsor
- UNICANCER
Digestive Cancer
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer
This study is to determine the Regorafenib Dose (RD) for the phase II trial of Regorafenib administered in combination with mGEMOX in patients with advanced biliary tract cancer.
- Trial name
- BREGO (NCT02386397)
- Testing
- Regorafenib, GEMOX
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Biliary Tract Cancer
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
This is a prospective, open-label, single-center clinical study, to evaluate the efficacy and safety of Capecitabine combined with Lenvatinib and Tislelizumab as adjuvant treatment after resection in patients with biliary tract…
- Trial name
- NCT05254847
- Testing
- Capecitabine combined with lenvatinib and tislelizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Biliary Tract Cancer, Periampullary Adenocarcinoma
SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer
This is an exploratory, single-armed, open label study on the efficacy and safety of sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary system or periampullary cancer or pancreatic cancer…
- Conditions
- Biliary Tract Cancer, Periampullary Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT01811277
- Testing
- SOX sequential S-1
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Resectable Biliary Tract Cancer
Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
The purposed of this research is to study the safety and clinical activity of the combination of nivolumab and cabiralizumab in people with resectable biliary tract cancers (BTC).
- Trial name
- NCT03768531
- Testing
- Nivolumab, Cabrilizumab
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Biliary Tract Cancer
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Pemetrexed in combination with erlotinib as a salvage treatment in patients with metastatic biliary tract cancer (BTC) who failed gemcitabine containing chemotherapy
- Trial name
- NCT03110484
- Testing
- Pemetrexed 500 MG, Erlotinib
- Where
- 2 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Samsung Medical Center
Unresectable Biliary Tract Cancer
Salvage mFOLFOX in BTC After Failure of Gemcitabine
The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine.
- Trial name
- NCT01127555
- Testing
- 5-fluorouracil, leucovorin, oxaliplatin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Chung-Ang University
Biliary Tract Cancer (BTC)
A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER
The REVEAL-BTC Study will analyze 5 biomarkes in samples of participants who in the past 15 year have been diagnosed with any stage of biliary tract cancer.
- Trial name
- REVEAL-BTC (NCT07515950)
- Testing
- No intervention
- Volunteers
- 244 people
- Sponsor
- MedSIR
Biliary Tract Cancer (BTC)
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
This study will evaluate the efficacy and safety of Oncolytic virus H101 combined with lenvatinib plus Toripalimab compared with FOLFOX in patients with advanced biliary tract cancer (BTC) who have progressed after first-line…
- Trial name
- NCT06919848
- Testing
- TORIPALIMAB INJECTION(JS001 ), Lenvatinib, H101
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fudan University
Biliary Tract Cancer (BTC)
Prospective AI-Assisted Screening of Biliary Tract Cancer Using Non-Contrast CT
Biliary tract cancer is a group of malignant tumors involving the intrahepatic bile ducts, extrahepatic bile ducts, and gallbladder.
- Trial name
- BTC-NCCT-AI (NCT07911397)
- Testing
- AI-Assisted Biliary Tract Cancer Screening Using NCCT
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Biliary Tract Cancer
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
The aim of this study is to assess the efficacy and safety of durvalumab combined with S-1 as adjuvant therapy of resectable Biliary Tract Cancer(BTC) with high risk of recurrence
- Trial name
- NCT06490107
- Testing
- Durvalumab combined with S-1
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences